Regulatory

Source: Business Wire, May 2019 OXFORD, England & CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announces that the U.S. Food and Drug Administration (FDA) has granted…

Source: Science Daily, May 2019 Melanomas tend to be “hot" or “cold" — if they’re hot, immunotherapy lights melanoma tumors like beacons for elimination by the immune system; but 40-50…

Source: Targeted Oncology, May 2019 The FDA has granted tebentafusp (IMCgp100) a fast track designation for the treatment of patients with HLA-A*0201-positive previously untreated metastatic uveal melanoma, according to Immunocore…

Source: Immuno-Oncology News, March 2019 The U.S. Food and Drug Administration has approved the use of Keytruda(pembrolizumab) as a treatment for melanoma patients with stage 3 disease — cancer cells have…